Home | AML Hub

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Steering Committee About Us Newsletter Contact

Visit:

Steering Committee About Us Newsletter Contact

Types Therapeutics Congresses Trials Expert Opinions

NCRI Academy 2020

AML Types

Phase III ASTRAL-2 and -3 trials of guadecitabine in patients with previously treated AML, MDS, or CMML fail to meet primary endpoints

On October 14, 2020, it was announced that the phase III trials ASTRAL-2 (NCT02920008) and ASTRAL-3 (NCT02907359)...

Oct 19, 2020

| s-AML

HOVON 116 trial: Epigenetic therapy with panobinostat and/or decitabine after allo-SCT for poor-risk AML

Allogeneic stem cell transplantation (allo-SCT) is the current standard of care for patients with poor-risk acute myeloid leukemia (AML).1...

Oct 16, 2020

| De novo

Regenerative medicine advanced therapy and orphan drug designation given to ORCA-T

The U.S. Food and Drug Administration (FDA) has granted both orphan drug designation and regenerative medicine advanced therapy (RMAT) to ORCA-T, an investigational...

Oct 15, 2020

| De novo

Coinhibition of BCL-2 and NHE1 pathways may have a potential to overcome venetoclax resistance

BCL-2, BCL-XI, along with MCL-1 proteins are known to play a significant role in tumor cell survival with anti-apoptotic properties. Venetoclax, a BCL-2...

Oct 15, 2020

Gert Ossenkoppele

" The AML Hub disseminates the most up-to-date information on AML for academic researchers and treating clinicians worldwide, to help improve their understanding of the latest advances in terms of research, biology, and treatment options. "

Featured Expert Opinion

Gert Ossenkoppele explains why you should join the virtual AML Hub Satellite Symposium

The AML Hub will hold a virtual satellite symposium at the 46th Annual Meeting of the...

MRD Symposium

AML Hub Satellite Symposium highlights: How does MRD impact outcome of stem cell transplantation in AML – now and in the future?

At the 46th Annual Meeting of the European Society for Blood and Marrow...

Sep 22, 2020

| MRD Symposium

AML Hub Satellite Symposium: Round table discussion and conclusions from the Chair

The virtual AML Hub Satellite Symposium at the 46th Annual Meeting of the European Society for Blood and Marrow...

Sep 21, 2020

| MRD Symposium

Why should we use MRD assessment post hematopoietic stem cell transplantation?

Professor Charles Craddock, University of Birmingham, Birmingham, UK, presented the topic ‘Why should we use MRD...

Sep 18, 2020

| MRD Symposium

Does current evidence support the use of MRD-guided treatment before transplant in patients with AML?

Professor Adriano Venditti, University of Rome Tor Vergata, Rome, IT, presented the topic ‘Does...

Sep 17, 2020

| MRD Symposium

FLT3 inhibitors

What are the highlights of SOHO 2020?

Interview with Selina M. Luger who discusses the highlights in AML from SOHO 2020.

Sep 25, 2020

| SOHO 2020

Gilteritinib in FLT3 AML

Interview with Steering Committee Member Naval Daver about gilteritinib for the treatment of FLT3 AML.

Sep 21, 2020

| SOHO 2020

Addition of midostaurin to frontline 7+3: A case report

During the 2nd How to Diagnose and Treat Acute Leukaemia conference of the European School of Haematology (ESH), our AML Hub Executive Steering...

Aug 17, 2020

| ESH 2020

LDAC plus AC220: Results from the LI-1 trial in older patients with AML

During the 25th European Hematology Association (EHA) Annual Congress 2020, Mike Dennis presented an oral abstract on the...

Aug 7, 2020

Chromosomal aberrations

Gemtuzumab ozogamicin for salvage CBF-AML: A case report

During the 2nd How to Diagnose and Treat Acute Leukaemia conference organized by the European School of Haematology (ESH), there was an...

Aug 28, 2020

| ESH 2020

APR-246 plus azacitidine for patients with TP53 mutated MDS and AML

The GFM-APR trial is investigating the safety and efficacy of APR-246 plus AZA as maintenance therapy for patients with TP53 mutant...

Jul 30, 2020

| EHA 2020

Can CD47 antibody therapy be safely used for AML and MDS?

Podcast discussion between David Sallman, Moffitt Cancer Center, and Naval Daver, MD Anderson Cancer Center, held during the 25th Congress of...

Jun 22, 2020

| EHA 2020

The role of the Nlrp3 inflammasome in hematological pathologies

The Nlrp3 inflammasome has recently gained a lot of attention due to its reported involvement in various hematological pathologies,...

Jun 18, 2020

Most Viewed

Gilteritinib in FLT3 AML

What’s next in AML?

What has the SAMBA trial taught us about the treatment of elderly high-risk AML/MDS patients?

How have venetoclax combinations changed the way we treat AML?

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Visit:

AML Types

Phase III ASTRAL-2 and -3 trials of guadecitabine in patients with previously treated AML, MDS, or CMML fail to meet primary endpoints

Oct 19, 2020

| s-AML

Oct 16, 2020

| De novo

Oct 15, 2020

| De novo

Oct 15, 2020

| EBMT 2020

Gert Ossenkoppele

MRD Symposium

Sep 22, 2020

| MRD Symposium

Sep 21, 2020

| MRD Symposium

Sep 18, 2020

| MRD Symposium

Sep 17, 2020

| MRD Symposium

FLT3 inhibitors

Sep 25, 2020

| SOHO 2020

Sep 21, 2020

| SOHO 2020

Aug 17, 2020

| ESH 2020

Aug 7, 2020

Most Read

Chromosomal aberrations

Aug 28, 2020

| ESH 2020

Jul 30, 2020

| EHA 2020

Jun 22, 2020

| EHA 2020

Jun 18, 2020

Most Viewed